Melanoma is known as a “cold” tumor due to the poor responses to ICI therapy; the combination of B‐Raf Proto‐Oncogene, serine/threonine kinase (BRAF) and Methyl Ethyl Ketone (MEK) inhibitors (BRAFi + MEKi) is an FDA‐approved approach to therapy BRAF V600E/K‐mutant melanoma. Here, MARK2 is linked to melanoma.